AUTL - Autolus Therapeutics' obe-cel shows high clinical activity in blood cancers shares rise 5%

Autolus Therapeutics (AUTL) presents data related to AUTO1 (obecabtagene autoleucel, obe-cel) in relapsed/refractory (r/r) indolent B cell lymphomas ((IBCL)) and r/r adult Acute Lymphoblastic Leukemia ((ALL)) at EHA 2021. AUTO1 results in r/r IBCL patients:As of the data cut-off date of May 17, 2021, 13 patients had been enrolled and product was successfully manufactured for 12 patients, with one patient’s cells ongoing in manufacture.Of these, 9 patients had received AUTO1 infusion. Three patients were pending infusion and one patient died prior to lymphodepletion due to a COVID-19.Obe-cel was well tolerated and demonstrated a favorable safety profile in adult patients with r/r low grade B-cell lymphoma, despite high disease burden.All treated patients achieved a complete metabolic remission and had robust CAR T engraftment, expansion, and persistence. AUTO1 data in r/r ALL:As of the data cut-off, 20 patients had received obe-cel. The therapy was well tolerated, with no patients experiencing Grade 3 or

For further details see:

Autolus Therapeutics' obe-cel shows high clinical activity in blood cancers, shares rise 5%